These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 17018129)

  • 1. Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood.
    Lowenstein H; Shah A; Chant A; Khan A
    Transpl Int; 2006 Nov; 19(11):927-36. PubMed ID: 17018129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD52 ligation induces CD4 and CD8 down modulation in vivo and in vitro.
    Shah A; Lowenstein H; Chant A; Khan A
    Transpl Int; 2006 Sep; 19(9):749-58. PubMed ID: 16918536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
    Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
    Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H.
    Birhiray RE; Shaw G; Guldan S; Rudolf D; Delmastro D; Santabarbara P; Brettman L
    Leukemia; 2002 May; 16(5):861-4. PubMed ID: 11986948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis.
    Golay J; Cortiana C; Manganini M; Cazzaniga G; Salvi A; Spinelli O; Bassan R; Barbui T; Biondi A; Rambaldi A; Introna M
    Haematologica; 2006 Mar; 91(3):322-30. PubMed ID: 16531255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment.
    Brett SJ; Baxter G; Cooper H; Rowan W; Regan T; Tite J; Rapson N
    Int Immunol; 1996 Mar; 8(3):325-34. PubMed ID: 8671618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
    Trzonkowski P; Zilvetti M; Friend P; Wood KJ
    Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes.
    Rowan WC; Hale G; Tite JP; Brett SJ
    Int Immunol; 1995 Jan; 7(1):69-77. PubMed ID: 7718516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
    Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
    Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of CAMPATH-1H in skeletal tumours.
    Fritsche-Guenther R; Gruetzkau A; Noske A; Melcher I; Schaser KD; Schlag PM; Kasper HU; Krenn V; Sers C
    Histopathology; 2010 Dec; 57(6):851-61. PubMed ID: 21166699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Campath-1H does not alter bone marrow cell regulatory function.
    Jin Y; Fuller L; Rosen A; Ciancio G; Burke GW; Ricordi C; Tzakis AG; Miller J; Esquenazi V
    Hum Immunol; 2005 Jun; 66(6):637-43. PubMed ID: 15993709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
    Ginaldi L; De Martinis M; Matutes E; Farahat N; Morilla R; Dyer MJ; Catovsky D
    Leuk Res; 1998 Feb; 22(2):185-91. PubMed ID: 9593475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early emergence of PNH-like T cells after allogeneic stem cell transplants utilising CAMPATH-1H for T cell depletion.
    Garland RJ; Groves SJ; Diamanti P; West SE; Winship KL; Virgo PF; Robinson SP; Oakhill A; Cornish JM; Pamphilon DH; Marks DI; Goulden NJ; Steward CG
    Bone Marrow Transplant; 2005 Aug; 36(3):237-44. PubMed ID: 15968291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1.
    Dreger P; Viehmann K; Steinmann J; Eckstein V; Müller-Ruchholtz W; Löffler H; Schmitz N
    Exp Hematol; 1995 Feb; 23(2):147-54. PubMed ID: 7530212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effect of sodium arsenite during the activation of human CD4+ and CD8+ T lymphocytes.
    Tenorio EP; Saavedra R
    Int Immunopharmacol; 2005 Dec; 5(13-14):1853-69. PubMed ID: 16275621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.
    Watanabe T; Masuyama J; Sohma Y; Inazawa H; Horie K; Kojima K; Uemura Y; Aoki Y; Kaga S; Minota S; Tanaka T; Yamaguchi Y; Kobayashi T; Serizawa I
    Clin Immunol; 2006 Sep; 120(3):247-59. PubMed ID: 16797237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies.
    Dyer MJ
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):52-7. PubMed ID: 10561018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocyte depletion and repopulation in peripheral blood and small intestine of cynomolgus monkeys after alemtuzumab treatment.
    Shan T; Qu L; Zhang J; Li Q; Shen B; Gu L; Jiang J; Feng X; Li N; Li J
    J Surg Res; 2011 May; 167(1):e21-7. PubMed ID: 20888596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptotic killing of CD4+ T lymphocytes in HIV-1-infected PHA-stimulated PBL cultures is mediated by CD8+ LAK cells.
    Wang L; Klimpel GR; Planas JM; Li H; Cloyd MW
    Virology; 1998 Feb; 241(2):169-80. PubMed ID: 9499792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism.
    Mone AP; Cheney C; Banks AL; Tridandapani S; Mehter N; Guster S; Lin T; Eisenbeis CF; Young DC; Byrd JC
    Leukemia; 2006 Feb; 20(2):272-9. PubMed ID: 16341049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.